Tarsons Products Limited has informed the Exchange about Investor Presentation
Date: 6th November, 2022
To, The Manager Listing Department BSE Limited, Phiroze Jee Jee Bhoy Towers, Dalal Street, Mumbai – 400001
BSE Scrip code: 543399 ISIN: INE144Z01023
An ISO 9001 & ISO 13485 Certified Company
To, The Manager Listing Department National Stock Exchange of Limited, Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra – Kurla Complex, Bandra, Mumbai-400051 NSE Symbol: TARSONS ISIN: INE144Z01023
India
Subject: Investors Presentation- for Quarter ended 30th September, 2022
Dear Sir/Madam,
Pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we are enclosing herewith an Investors Presentation on the Operational & Financial Highlights for the quarter ended 30th September, 2022.
The Presentation will also be uploaded on the Company’s website at www.tarsons.com.
We request you to kindly take the same on your records.
Thanking you,
Yours Faithfully, For Tarsons Products Limited (Formerly Tarsons Products Private Limited)
Santosh Kumar Agarwal Company Secretary and Chief Financial Officer Membership No. 44836
Encl: As above
Tarsons Products Limited, 902, Martin Burn Business Park, BP-3, Sector –V, Salt Lake, Kolkata – 700091 Tel: +91 33 3522 0300, Web: www.tarsons.com Mail: info@tarsons.com, CIN: L51109WB1983PLC036510
TARSONS PRODUCTS LIMITED Investor Presentation - November 2022
arsons
TRUST
DELIVERED
Leading player in the domestic plastic labware market and presence over 40 countries across the Globe
Safe Harbor
arsons
TRUST DELIVERED
This presentation and the accompanying slides (the “Presentation”), which have been prepared by Tarsons Products Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.
This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.
Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections.
All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness
2
Tarsons – at a Glance
One of the leading Indian labware company engaged in the designing, development, manufacturing and marketing of consumables, reusables and others (including benchtop equipment & instruments)
Products used in laboratories across research organizations, academia institutes, pharmaceutical companies, CROs, diagnostic companies and hospitals
39+ years of experience in the life sciences industry delivering trusted high-quality products.
Robust market share in the highly fragmented Indian labware market*
Diversified product portfolio with 1,700+ SKUs across 300 product segment
,
------
5 vertically integrated manufacturing facilities in West Bengal
------
Pan-India distribution network with long-standing relationships with the distributors
One of the few players in India to have a global reach# in the labware market with 45+ authorized distributors & partners supplying products to over 40 countries
*Approximately 9-12% as per Frost & Sullivan Industry Report 2021 #As per Frost & Sullivan Industry Report 2021
3
Our Journey
Incorporation of TPL with manufacturing of reusable plastic products
Expanded product line by initiating manufacturing of Centrifuge Tubes
Became an ISO 9001 certified manufacturing entity
Obtained ISO 13485:2016/NS- EN certificate for manufacturing facility
Acquired 5 acres of land in Panchla & 6 acres of land in Amta to develop another facility for capacity expansion, introduction of new product lines, backward integration & fulfillment center
Got listed on Stock Exchanges
1983
1984
1987
2002
2009
2012
2018
2019
2021- 2022
Commenced production of Pipette Tips, thereby creating a high-quality import substitute
Pioneered the first fully robotic clean room plant for manufacturing molecular biology consumables
Setup manufacturing facility expanding into production of fully automatic centrifuge tubes, and cryogenic vials in Dhulagarh
Set up line for PCR products in Jalan Industrial Complex at Jangalpur
Leading Indian Labware Supplier
arsons
TRUST DELIVERED
Trusted Brand for high quality products in the plastic labware market with 39+ years vintage in the industry
Expertise in production of a wide range of labware products & amongst the top 3 players with a robust market share*
Ability to offer differentiated, user friendly, reliable quality & cost-effective products has enabled strong brand recognition & customer loyalty
Individual product brands like Maxipense, Spinwin, Cryochill are well- recognized by the scientific community
Pioneered the first fully automated plant for manufacturing molecular biology consumables
In-house engineering team driving innovation & ensuring exceptional liquid handling performance across the liquid handling products
Source*: As per Frost & Sullivan Industry Report 2021
5
Our Competitive Edge
arsons
TRUST DELIVERED
Geographical Presence Wide geographic reach through a strong sales & distribution network
03
04
State of Art Facilities Well-equipped and advanced automation driven manufacturing facilities
02
Diversified Customers Long-standing relationships with a diverse set of key end-customers
01
Brand & Quality Leading Indian supplier to the life sciences sector with strong brand recognition and high- quality diversified products across varied customer segments.
Experienced Management Team Experienced promoter supported by a highly competent management team and backed by board of directors comprising of industry veterans
Financial Stability Financial track record with efficient capital allocation & streamlined operations ensuring consistent high profitability
05
06
6
Catering to diversified End User Industry…
arsons
TRUST OELIVERED
Plnebs"
NltIonIICentfffofBlolooICIIScltn«. T.t.I""h~l.o'Fund.m,"I.IA... an:1I
Academic Institutes & Research Organization
National Centre for Biological Sciences
Indian Institute of Chemical Technology
Rain Forest Research Institute
KIIT University
Pharmaceutical Industry
••• Dr. Reddy's ~~.
Dr. Reddy's Laboratories Limited
Syngene
••
vee d a clinicalresearch.
Contract Research Organization
Syngene International Limited
Veeda Clinical Research Limited
ft.;........~
··'''·~~ENZENE :- Blosclences Ltd .
•
Enzene Biosciences Limited
TCG Lifesciences
EruWin& lran~~tionalH@diciRl!
TCG Lifesciences Private Limited
METROPi)LlS
Ttlc PathologySpcclalist
AGAPPE
• ~~b Lifesolutions
Diagnostics Industry
Dr Lal Pathlabs Limited
Metropolis Healthcare Limited
Molbio Diagnostics Private Limited
OFavantor'·
Agappe Diagnostics Limited
..icell
Mylab Lifesolutions Private Limited
Toei Kaisha
Exports Market
Avantor, Inc
FC-BIOS SDN BHD
iCell INC
Toei Kaisha Limited
1
2
3
4
5
6
Measures to strengthen customer relations
Regular Feedback from Customers on quality, delivery & cost
Maintaining leading industry & Regulatory Compliance Standards
Product Customization as per the customer’s specific needs
Adherence to Quality standards & Safety Protocols in place
Wide Range of Products
50-member Sales Team with deeply entrenched relationships
7
Our State-of-the-art Manufacturing Facilities…
Land Area (in sq. mts.)
Ownership
Mfg Revenue Contribution (FY22)
530
1,022
515
15,142
4,047
21,550
24,080
Leased
Leased
Leased
Owned
Leased
Owned
Owned
5.0%
6.4%
2.0%
62.1%
24.5%
-
-
Units
Burroshibtolla I
Burroshibtolla II
Kasba
Jangalpur
Dhulagarh
Panchla
Amta
Upcoming Facility
Key Highlights of the High Precision Manufacturing Process
✓ Vertically integrated manufacturing capabilities with design
& development being carried out in-house
✓ Automated manufacturing with use of robotics & other technologies developed in collaboration with overseas partners
✓ Production process free from human touch & thus helps to achieve the desired levels of purity required for use in life sciences products
✓ Manufactured in clean aseptic environment;
manufacturing process is carried out in fully-validated & 3rd-party certified ISO 8 clean rooms
✓ Quality Certifications: ISO & CE certifications
✓ Company is developing a new fulfillment center with in- house sterilization capability in Amta, West Bengal, for which the land has been acquired
✓ Company is expanding into new products at upcoming
production facility in Panchla, West Bengal
8
…with widespread Domestic Sales & Distribution network…
arsons
TRUST DELIVERED
Comprehensive Pan-India Distribution Network
Long-standing relationships with Distributors
North: 20% of FY22 Domestic Sales 42 Distributors
East: 19% of FY22 Domestic Sales 42 Distributors
West: 23% of FY22 Domestic Sales 18 Distributors
South: 38% of FY22 Domestic Sales 39 Distributors
Data as on FY22
All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness
9
…with huge underlying Export Market Potential…
Huge Export Opportunity Market
One of the very few players to have a Global Reach
Demand for plasticware expected to grow at 10% CAGR for developing markets like APAC & MEA, developed markets like Americas & Europe also expected to grow healthy
✓ As of 31st March 2022, the company sold its products to 40+ countries via 45+
distributors
✓ Export operations are a blend of branded and ODM sales
✓ Under the ODM model, the product is independently designed & developed by the
company as per the requirements given & then sold to the respective brand owners
Factors such as supplier reliability, cultivating new relationships, deepening existing relationships and meeting demands in timely manner will enhance the export market share
Rapid increase in demand for plasticware is providing platform for Indian players to expand share of export revenues while continuing import substitution at home
Export Revenue (INR mn)
Export Revenue Break-up (%)
993
FY19
FY22
480
35%
43%
65%
57%
Established Indian players can further expand export market share on back 0 of high-quality & reliable products with 4 enhanced R&D and independent design & customization capabilities
Domestic companies in India can take advantage of their competitive pricing 0 in order to capture larger share of global market 3
FY19
FY22
Branded
ODM
Key Overseas Clients (ODM Sales)
aI cvontor
e.iceLl
Toei Kaisha
10
…offering Wide Range of High-Quality Products…
TRUST DELIVERED
Our products are made from high-quality medical grade DMF registered resins which are selected to minimize additives & reduce potential leachables
Consumables
63% of FY22 Revenues
• Portfolio of products under this category
include: • Centrifuge ware • Cryogenic ware (tubes & accessories) • PCR consumables (tubes, plates, and
strips) • Petri dish • Pipettes
t
Reusables
33% of FY22 Revenues
• Portfolio of products under this category
include: • Bottles & Carboys • Beakers • Measuring cylinders • Racks • Others (jars, desiccators etc.) • High quality standards maintained to
ensure the products are leakage proof through specially designed lip-sealing geometry
Others
4% of FY22 Revenues
• Products under this category includes benchtop instrumentation such as:
• Vortex shakers • Centrifuges • Pipettors
• These products enable molecular works of
cell collection, extraction, simple spin-down and f-tube separation
Offering a Wide Range of Products enabling its end-customers to source most of their product needs from a Single Source
11
…diversified product portfolio of Plastic Labware
TRUST
DELIVERED
Pipette Tips
Centrifuge Tubes
Petri Dishes
Cryo Vials
Storage Vials
Mostly used in research work for transferring small volume of liquids with high precision
for versatile applications, Perfect these are used for storage, spinning down & separation of colloidal solution
•
• Mostly used in the culture of microbes and sensitivity assays Typically used once and discarded which optimizes time consumed in washing and sterilizing
storage of biological Used for materials at temperatures as low as -196°C (vapour phase of liquid nitrogen) and up to 121°C
Storage vials are designed for use with samples from -80°C to 121°C. Used for storage of PCR reagents, enzymes diagnostics, biochemical reagents or samples
other
and
Bottles
Carboys
Beakers
Cylinders
Benchtop Instruments
• Used
for
containment, protection and transportation of various kinds of reagents Leakproof, strong and durable
•
Used for media formulation and mixing, aseptic protocols, stirring and storage of intermediates
• Used for mixing; graduations are approximate and not intended for accurate liquid measurement Economical enough to discard after one use, or strong enough to reuse
•
Used to measure the volume of a chemicals, and solutions liquids, during daily lab work
• Wide
instrumentation
variety products which include vortex
benchtop shakers, centrifuges, pipettors Enable molecular works of cell collection, extraction, simple spin-down and f-tube separation
like
•
12
) s e l a S 2 2 Y F f o % 3 6 (
s e l b a m u s n o C
l
) s e a S 2 2 Y F f o % 7 3 (
s r e h t O & s e b a s u e R
l
Glimpse of our product portfolio & processes
TRUST
DELIVERED
Video link – Click here
Video link – Click here
Video link – Click here
Disco er a wide range of
'Lab are at Tarsons
Video link – Click here
Video link – Click here
For more information & videos please visit www.tarsons.com/video-new
13
Key Business Strategies
Key Business Strategies
• Focus on branding & promotion to enhance visibility in the labware industry to increase
brand awareness & loyalty
Enhance existing & expand product portfolio
• Manufacture New Products in the cell culture & robotic handled consumables and expand
into the import dominated markets of these products Leverage the advantage of “Make in India” and grow our domestic sales vis-à-vis exports
•
Enhance manufacturing capacities to leverage growth
• Expand manufacturing capacities in popular product categories like liquid handling, centrifuge
ware, & cryo ware through additional machines, moulds and ancillary infrastructure
• Acquired 5 acres of land to develop a new manufacturing facility in Panchla, West Bengal to
expand & enter into the new product segment comprising of cell culture
• Also, acquired 6 acres of land at Amta to develop fulfilment center, radiation facility and
manufacture few products
• Plans to export to ~120 countries in the next 5-10 years through the extensive experience and
proven track record of catering to overseas customers
• Two-pronged approach:
Increasing presence in overseas markets
• Branded sales targeting emerging markets such as Asia Pacific, Middle East and South America • ODM sales to supply products to developed markets such as USA and Europe
Maintain operational efficiency & profitability
•
Implemented strategic cost-saving and efficiency improvement processes such as advanced automation solutions to improve productivity which resulted in a ~58% PAT CAGR from FY20 to FY22
• Continue to invest in automation in order to avoid human error & consequently improve
throughput
14
Experienced Board of Director & Managerial Team
TRUST
DELIVERED
Sanjive Sehgal Chairman & Managing Director
• Chairman & Managing Director of Tarsons Product
Limited
• Has over 31 years of experience in the company
Rohan Sehgal Whole Time Director
• Whole-time Director of the company • Has over 8 years of experience working in the
company
Santosh Agarwal Chief Financial Officer & Company Secretary
• Qualified as a Chartered Accountant & Company
Secretary
• Has over 21 years of experience
Gaurav Podar Non-Executive Nominee Director
• Currently, Director with ADV Partners •
Investment professional with 11+ years of experience
Girish Vanvari Independent Director
•
Founder of Transaction Square – a Tax, Regulatory & Business Advisory Firm
• Qualified as a Chartered Accountant
Sucharita Basu Independent Director
• Co-founder AQUILAW • 21+ years of experience in commercial & corporate
agreements, capital markets & real estate
Viresh Oberai Independent Director
• 22+ years experience with Tata Steel • Conferred with “Udyog Rattan” award from Indian Economics
Society
15
Contribution towards Environmental, Social & Governance
Clean room conditions eliminates all chances of contamination
Productivity optimisation with use of high automation
Use of Medical Grade Plastics. Products are designed to withstand critical use
NO Hazardous materials consumed
NO litigations faced for pollution or degradation of environment over the past five years
NO impact of Climate change
Employee Welfare: Multi- pronged approach towards employee development.
Company has NOT witnessed any employee unrest / strikes or lockouts since inception
The Board has an optimum combination of Executive and Non- Executive directors
Company has Clean Track Record of Liability payments to various stakeholders
Some of the CSR activities has been directed towards TATA Cancer Hospital & Narayana Hrudayala
Regular Review & Updation of policies for change requirements.
Whistleblower policy implemented
16
DELIVERING
TRUST
Across 40 countries, our range of quality labware products help achieve scientific discovery and improve healthcare.
Industry Update
HlGHUGHTS • An Indian company' engaged in the designing, development. manufacturing and marketing of labware products used in various laboratories and research organlutions
• SUpplyto over 40countries across both developed
and emerging markets
• F1ve tmnUfilCturing facilities located In West Bengal
• Diverslfoed product portfolio with over 1,700 SKUs
across 300 products, as of June 30,2021
• With over three decades' of experience serving life sciencessuccessfully built 'Tarsons' inlO a leading Indian company In terms of revenue In the plastlc labware market In India
arsons
TRUST
DELIVERED
Plastic Labware Market
arsons
TRUST DELIVERED
Indian plastic labware market is expected to grow at 16% CAGR from 2020-2025
Split of Global Market Size of Plastic Labware (2020)
Global Laboratory Equipment Market Size (INR Bn)
Indian Laboratory Equipment Market Size (INR Bn)
1,131
589
1,437
969
34
26
24
12
FY20
FY25
FY20
FY25
Labware
Only Plasticware
▪ Expected increase in investments by various pharmaceutical majors to advance research
into various chronic diseases treatment
▪ COVID-19 pandemic has led to an increase in long term demand for laboratory
investigations, vaccine development activities and clinical trials
▪ Key growth drivers of the Indian market include:
Urbanization & growing middle class coupled with sedentary lifestyles are resulting in increasing incidence of chronic diseases which in turn drive healthcare research & demand for labware products
−
−
−
Certrifuge ware
14%
▪ Centrifuge & Liquid Handling market dominate the Laboratory equipment market
Liquid handling
26%
41%
PCR & Cell/ Tissue Culture
▪ The automated liquid handling market is anticipated to witness a significant market growth during the forecast period
6%
Bottles & Carboys
6% Cryoware
▪ PCR product segment has seen a strong growth lately due to high demand on account of the pandemic
Diagnostic Labs
Others 4%
24%
IVF Clinics
3%
11%
Academia/ Research
31%
▪ The Academia/Research and
Pharmaceutical segments contribute to majority of the end use making up ~60%
▪ With strong increase in outsourcing by
pharma companies, CROs are expected to grow strongly
▪ Diagnostic labs are expected to grow
at a robust pace on account of increasing awareness and need of testing
Highly underpenetrated healthcare sector provides significant room for growth
CROs
27%
Growth in pharmaceutical R&D outsourcing to India will serve as a huge catalyst for the labware space
Pharmaceutical
Source: As per Frost & Sullivan Industry Report 2021
18
Rapid Shift from Glassware to Plasticware in India
arsons
TRUST DELIVERED
Indian Laboratory Equipment Market (Breakup of Glassware and Plasticware segments)
Market Size
INR 10.8 bn
INR 7.5 bn
INR 11.3 bn INR 12.2 bn
INR 8.4 bn
INR 25.8 bn
18.3
59.0%
41.0%
2015
23.5
48.0%
52.0%
2020
34.2
25.0%
75.0%
2025
Glassware Products
Plasticware Products
Key reasons for the shift:
▪ Increased Applicability: Superior ability to handle radioactive isotopes, hazardous & carcinogenic chemicals or substances ▪ Enhanced Safety: Inherent characteristics of plasticware including thermo-stability & safety of laboratory personnel in case of
accidents
▪ Less Contamination: Samples stored in glass containers are prone to contamination due to leaching of inorganic ions into
aqueous solutions or exposure to light in case of light-sensitive materials; thus, making plasticware a preferred choice vis-à-vis glassware
▪ Ease of Handling : Plastic Labware is significantly lighter in weight and much easier to handle over long hours than glassware ▪ Durability: Plastic equipment is unbreakable & has a longer shelf life as well allowing for better use & flexibility to scientists &
researchers
▪ Cost Effective: Plastic Labware is more cost effective than glassware
India Plasticware Laboratory Consumables Market by Product Type (INR mn)
India Plasticware Laboratory Reusables Market by Product Type (INRmn)
India Plasticware Laboratory PCR/Cell Culture Market by Product Type (INR mn)
71
3,279 332 1,253 1,622
2015
120
4,945
548 1,883
2,395
2020
10,050
247
1,167
3,698
4,938
2025F
1,132
49
1,083
2015
1,833 95 1,738
2020
3,161
133
3,028
2025F
Centrifuge Ware
Liquid Handling
Cryoware
Others
Bottles, Beakers, Flasks & Carboys
Others
3,105
257
2,848
2015
5,473 398 5,075
2020 PCR, Cell Culture
Others
12,544
825
11,719
2025F
▪ Centrifuge ware is largest segment within consumables with 48% market share ▪ Increased investments in life sciences sector including omics research, advanced healthcare, microbiology, drug development, and clinical diagnostics are key factors supporting higher usage of laboratory products
▪ India being a vaccine manufacturing hub is also a driving point for use of laboratory ware especially consumables for quality testing and approvals
▪ India being price sensitive country prefers plastic reusables as they have long shelf life in addition to being unbreakable and inexpensive as compared to glass
▪ Increase in automation in biotech & diagnostic labs will boost demand for
plasticware reusables where storage and machine handling requires products with better flexibility and dexterity
▪ Cell / Tissue Culture is high end, large & growing market in India with huge
potential for growth
▪ Increase in R&D in field of cell engineering is also expected to propel growth
of cell culture supplies market
▪ Stringent license and accreditation procedures involved with maintaining
cell cultures allow only specific companies to operate in the market
Source: As per Frost & Sullivan Industry Report 2021
19
RELIABILITY
•Presence in 40 countries
*1,700 SKUs
* 300 Products
Q2 FY23 Financial Highlights
arsons
TRUST DE:LIVERED
Q2 FY23 Key Financial Highlights
arsons
TRUST DELIVERED
Revenue (in Rs. Crs)
EBIDTA (in Rs. Crs)
Profit After Tax (in Rs. Crs)
Higher share of Covid related sales
Higher share of conventional business
76.0
68.6
71.2
38.5
Commodity inflation, Marketing expenses & investments in manpower to support future growth impacted EBITDA
31.1
32.7
24.9
20.3
21.5
Q2FY22
Q1FY23
Q2FY23
Q2FY22
Q1FY23
Q2FY23
Q2FY22
Q1FY23
Q2FY23
GP Margin (%)
EBIDTA Margin (%)
PAT Margin (%)
79.1%
79.1%
76.8%
50.6%
45.4%
45.9%
32.7%
29.6%
30.1%
Q2FY22
Q1FY23
Q2FY23
Q2FY22
Q1FY23
Q2FY23
Q2FY22
Q1FY23
Q2FY23
➢ Revenue for Q2FY23 stood at Rs. 71.2 crs as compared to Rs. 76.0 crs in Q2FY22
➢ Dip in the revenue was on account of high share of covid related revenues during H1 of FY22.
➢ On a like-to-like basis, our conventional business has witnessed resilient YoY growth and we expect this to continue going forward
➢ Gross margin in Q2FY23 was impacted due to a change in product mix and inflationary commodity environment on tensions & account of geo-political supply chain disruptions
➢ EBIDTA for Q2FY23 stood at Rs. 32.7 crs as compared to Rs. 38.5 crs in Q2FY22
➢ EBIDTA margins have been impacted on for our facility & Marketing & expenses exports in the future growth to fuel our
account of manpower cost upcoming Branding markets engines
21
Q2 FY23 Key Operational Highlights
arsons
TRUST DELIVERED
(in Rs. Crs)
145
140
76
52
25
71
44
-14%
+11%
27
103
93
-10%
42
+12%
47
t r o p x E : c i t s e m o D – t l i
p S e u n e v e R
32%
29%
Q2FY22
68%
H1FY22
71%
38%
Q2FY23
62%
34%
H1FY23
66%
Q2FY22
Q2FY23
H1FY22
H1FY23
Domestic
Exports
➢ Our export business revenues grew by 11% & 12% on Y-o-Y basis for Q2FY23 & H1FY23 respectively. Our constant endeavor to increase our presence in the global markets
are yielding results
➢ Off the total exports revenue; 41% was contributed by branded products & 59% by ODM sales in Q2FY23. For H1FY23, 35% was contributed by branded products & 65% by
ODM sales
➢ Domestic revenues were impacted on the back of high share of Covid related revenues in Q2FY22. Revenues for our conventional domestic business has grown substantially
on a Y-o-Y basis for Q2 & H1FY23
➢ Spilt across Domestic : Export revenues stood at 62:38 for Q2FY23 & for H1 FY23 it stood at 66:34
22
Q2 & H1 FY23 Profit & Loss Statement
arsons
TRUST DELIVERED
Profit and Loss (in Rs. Crs)
Revenue from Operations
Cost of Goods Solds
Gross Profit
Gross Profit Margin
Employee Cost
Other Expenses
EBITDA
EBITDA Margin
Depreciation
Other Income
EBIT
Finance Cost
Profit before Tax
Tax
Profit After Tax
Q2FY23
Q2FY22
71.2
16.6
54.7
76.0
15.9
60.1
76.8%
79.1%
8.8
13.2
32.7
7.6
14.0
38.5
45.9%
50.6%
6.9
3.7
29.5
0.7
28.8
7.3
21.5
4.8
1.4
35.1
1.6
33.5
8.6
24.9
YoY
-6.3%
-9.1%
-15.0%
-15.9%
-14.2%
-13.8%
Profit After Tax Margin
EPS
30.1%
4.03
32.7%
4.89
QoQ
3.8%
0.8%
5.0%
6.6%
5.6%
5.7%
Q1FY23
68.6
14.4
54.3
79.1%
8.3
14.9
31.1
45.4%
6.1
2.7
27.7
0.4
27.3
7.0
20.3
29.6%
3.82
H1FY23
H1FY22
139.9
30.9
109.0
77.9%
17.0
28.1
63.8
145.2
28.3
116.9
80.5%
15.3
26.4
75.2
45.6%
51.8%
13.0
6.4
57.2
1.2
56.0
14.3
41.8
29.9%
7.85
9.4
3.4
69.3
2.4
66.9
17.2
49.7
34.3%
9.77
YoY
-3.7%
-6.8%
-15.2%
-17.4%
-16.2%
-16.0%
23
Balance Sheet
Assets (in Rs. Crs)
Non - Current Assets
Property Plant & Equipment's
CWIP
Other Intangible assets
Right of use asset
Financial Assets
(i) Other Financial Assets
Current Tax Assets (Net)
Other Non Current Assets
Current Assets
Inventories
Financial Assets
(i) Trade receivables
(ii) Cash and cash equivalents
(iii) Bank balances other than (ii)
Other Financial Assets
Other Current Assets
Total Assets
Sept-22
Mar-22
Equity & Liabilities (in Rs. Crs)
Sept-22
Mar-22
arsons
TRUST DELIVERED
395.2
191.4
74.0
0.6
6.7
7.0
2.7
112.9
233.4
99.0
57.9
62.8
0.0
0.1
13.5
628.6
299.7
181.4
32.2
0.7
6.7
5.9
2.5
70.3
244.5
82.4
65.2
77.4
8.4
0.1
11.1
544.2
Total Equity
Share Capital
Other Equity
Non-Current Liabilities
Financial Liabilities
(i) Borrowings
(ii) Lease Liabilities
(iii) Other Financial Liabilities
Other Non Current Liabilities
Deferred Tax Liabilities
Current Liabilities
Financial Liabilities
(i) Borrowings
(ii) Trade Payables
(iii) Other Financial Liabilities
Other Current Liabilities
Current tax liabilities (net)
Provisions
531.8
10.6
521.1
21.7
10.8
0.0
0.1
6.1
4.7
489.9
10.6
479.2
19.5
9.3
0.0
0.1
5.6
4.4
75.0
34.9
50.8
9.3
9.2
3.2
2.1
0.4
12.3
13.0
3.5
4.7
0.0
1.5
Total Equity & Liabilities
628.6
544.2
24
Cash Flow Statement
Particulars (in Rs. Crs)
Net Profit Before Tax
Adjustments for: Non -Cash Items / Other Investment or Financial Items
Operating profit before working capital changes
Changes in working capital
Cash generated from Operations
Direct taxes paid (net of refund)
Net Cash from Operating Activities
Net Cash from Investing Activities
Net Cash from Financing Activities
Net Increase/Decrease in Cash and Cash equivalents
Add: Cash & Cash equivalents at the beginning of the period
Cash & Cash equivalents at the end of the period
arsons
TRUST DELIVERED
Sep-22
Sep-21
56.0
11.2
67.3
-20.7
46.6
-12.1
34.5
-88.0
38.9
-14.7
77.4
62.8
66.9
11.9
78.8
-36.0
42.9
-15.1
27.7
-81.7
69.6
15.6
2.3
17.9
25
Management Commentary
TRUST
DELIVERED
Commenting on the Q2 FY23 performance of the company Mr. Rohan Sehgal Said:
“Our revenues for Q2FY23 were down by 6% on a Y-o-Y basis and up by 4% on a Q-o-Q basis. If we compare on a like to like basis i.e. negating the high base of covid related revenues in H1FY22, our conventional business has shown a substantial growth. With addition in our product portfolio and wide network of distributors across India, we are confident of sustaining our growth in the domestic conventional business
Rohan Sehgal Whole Time Director
Our exports revenues have grown by 11% & 12% for Q2 & H1FY23 respectively. With expanding product portfolio and the Brand & Trust, ‘Tarsons’ have developed over the last 4 decades, we are confident of expanding our footprints in the global markets
Our capacity expansion is on track and the commissioning of the upcoming facility is expected to be in H1 FY24. We are confident of ramping up this facility in a short span because "Tarsons" as a brand has grown in popularity for quality products and timely delivery
Our strategy is to be present in all business segments of the life science industry, gain a significant share of the Indian market, and strengthen our presence in the export markets.”
26
Historical Consolidated Financial Highlights
arsons
TRUST DELIVERED
REVENUE (in Rs. Crs)
EBITDA (in Rs. Crs)
PAT (in Rs. Crs)
+31%
229
301
176
153
+48%
103
101
+58%
69
69
41
FY20
FY21
FY22
FY20
FY21
FY22
FY20
FY21
FY22
GP Margin
676 bps
72.3%
73.1%
79.1%
EBITDA Margin
1,139 bps
45.2%
50.8%
39.4%
PAT Margin
1,042 bps
30.1%
33.5%
23.0%
FY20
FY21
FY22
FY20
FY21
FY22
FY20
FY21
FY22
27
Historical Consolidated Profit & Loss Statement
arsons
TRUST DELIVERED
Profit and Loss (in Rs. Crs)
Revenue from Operations
Cost of Goods Solds
Gross Profit
Gross Profit Margin
Employee Cost
Other Expenses
EBITDA
EBITDA Margin
Depreciation
Other Income
EBIT
Finance Cost
Profit before Tax
Tax
Profit After Tax
Profit After Tax Margin
FY22
300.8
62.9
237.9
79.1%
31.4
53.8
152.7
50.8%
22.0
8.5
139.2
4.2
135.0
34.3
100.7
33.5%
FY21
228.9
61.5
167.4
73.1%
24.4
39.5
103.4
45.2%
13.7
5.4
95.2
2.7
92.4
23.6
68.9
FY20
175.9
48.7
127.2
72.3%
20.1
37.9
69.3
39.4%
14.2
4.2
59.2
6.1
53.1
12.6
40.5
30.1%
23.0%
CAGR
30.8%
36.7%
676 bps
48.5%
1,139 bps
53.3%
59.4%
57.6%
1,042 bps
28
Historical Consolidated Balance Sheet
arsons
TRUST DELIVERED
Assets (in Rs. Crs)
Non - Current Assets
Property Plant & Equipment's
CWIP
Other Intangible assets
Right of use asset
Intangible Assets under development
Financial Assets
(i) Other Financial Assets
Current Tax Assets (Net)
Other Non Current Assets
Current Assets
Inventories
Financial Assets
(i) Trade receivables
(ii) Cash and cash equivalents
(iii) Bank balances other than (ii)
Other Financial Assets
Other Current Assets
Total Assets
Mar-22
Mar-21
Mar-20
Equity & Liabilities (in Rs. Crs)
Mar-22
Mar-21
Mar-20
299.7
181.4
32.2
0.7
6.7
0.0
5.9
2.5
70.3
244.5
82.4
65.2
77.4
8.4
0.1
11.1
544.2
183.1
113.7
21.5
0.0
6.8
0.6
3.1
2.4
35.1
112.8
46.7
47.0
2.3
0.8
0.0
15.9
296.0
128.9
87.6
19.3
0.0
4.4
0.0
2.2
1.8
13.5
119.8
48.7
38.2
25.3
0.9
0.0
6.7
Total Equity
Share Capital
Other Equity
Non-Current Liabilities
Financial Liabilities
(i) Borrowings
(ii) Lease Liabilities
(iii) Other Financial Liabilities
Other Non Current Liabilities
Deferred Tax Liabilities
Current Liabilities
Financial Liabilities
(i) Borrowings
(ii) Trade Payables
(iii) Lease
(iv) Other Financial Liabilities
Other Current Liabilities
Provisions
489.9
10.6
479.2
19.5
9.3
0.0
0.1
5.6
4.4
244.3
197.6
0.2
244.1
9.8
0.2
197.4
10.7
3.3
0.0
0.1
3.2
3.3
5.9
0.0
0.1
1.5
3.2
34.9
41.8
40.4
12.3
13.0
0.0
3.5
4.7
1.5
30.2
30.0
6.0
0.0
2.7
1.4
1.5
5.9
0.0
1.9
1.5
1.1
248.7
Total Equity & Liabilities
544.2
296.0
248.7
29
Historical Consolidated Cash Flow Statement
arsons
TRUST DELIVERED
Particulars (in Rs. Crs)
Net Profit Before Tax
Adjustments for: Non -Cash Items / Other Investment or Financial Items
Operating profit before working capital changes
Changes in working capital
Cash generated from Operations
Direct taxes paid (net of refund)
Net Cash from Operating Activities
Net Cash from Investing Activities
Net Cash from Financing Activities
Net Increase/Decrease in Cash and Cash equivalents
Add: Cash & Cash equivalents at the beginning of the period
Exchange difference on translation of foreign currency
Cash & Cash equivalents at the end of the period
FY22
135.0
23.7
158.7
-41.8
116.8
-33.4
83.5
-137.9
129.6
75.1
2.3
0.0
77.4
FY21
92.4
15.8
108.2
-16.0
92.2
-24.1
68.2
-63.9
-27.2
-23.0
25.3
0.0
2.3
FY20
53.1
20.0
73.1
6.4
79.5
-15.3
64.2
-25.4
-13.8
25.0
0.5
-0.2
25.3
30
Key Ratios
Return on Equity
Return on Capital Employed
Return on Asset
Debt to Equity
28.2%
34.3%
23.3%
0.2
20.5%
20.6%
25.4%
27.2%
16.3%
18.5%
0.1
arsons
TRUST DELIVERED
0.0
FY20
FY21
FY22
FY20
FY21
FY22
FY20
FY21
FY22
FY20
FY21
FY22
Current Ratio
Working Capital (in Rs. Crs)
Working Capital Days*
Asset Turnover
7.0
135
136
3.0
2.7
81
88
114
104
0.7
0.8
0.6
FY20
FY21
FY22
FY20
FY21
FY22
FY20
FY21
FY22
FY20
FY21
FY22
*For WC; Debtors & Inventory calculated on Sales & Creditors on COGS
31
Key Takeaways
TRUST DELIVERED
Leading Indian manufacturer of labware with an established brand & focus on high-quality products
Presence in an industry with double- digit growth potential and multiple growth drivers
Long-standing relationships with 04 distributors catering to a diverse set of end-customers pan-India
arsons'
TRUST
DELIVERED
Financial profile with ~45% EBITDA margins & high ROCE coupled with double-digit growth rates
Highly automated state-of-the-art manufacturing facilities churning out quality products
Well-placed to grow domestic & export business through launch of new products & capacity expansion
32
Thank You
arsons
TRUST DELIVERED
Tarsons Products Limited
CIN: L51109WB1983PLC036510 Mr. Santosh Agarwal – Chief Financial Officer santosh@tarsons.in
SGA Strategic Growth Advisors
Strategic Growth Advisors Private Limited
CIN: U74140MH2010PTC204285 Mr. Sagar Shroff/Mr. Pratik Shah sagar.shroff@sgapl.net / p.s.shah@sgapl.net +91 98205 19303 / +91 98700 30585